Alector reports Q1 EPS (21c), consensus (28c)

Reports Q1 revenue $1.05M, consensus $11.03M. “Over the past seven years, we have built a highly differentiated blood-brain barrier platform with the versatility to deliver antibodies, enzymes, proteins, and siRNA to the brain,” said Arnon Rosenthal, Chief Executive Officer of Alector (ALEC). “We have a rich and growing pipeline of ABC-enabled programs, and we remain deeply committed to developing therapies that can make a meaningful difference for patients living with neurodegenerative diseases.”